INR 1404.7
(0.45%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 3.86 Billion INR | -34.14% |
2022 | 10.19 Billion INR | 16.61% |
2021 | 8.74 Billion INR | 20.12% |
2020 | 7.28 Billion INR | 19.89% |
2019 | 6.07 Billion INR | 16.27% |
2018 | 5.22 Billion INR | 13.26% |
2017 | 4.61 Billion INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 1.71 Billion INR | 0.64% |
2024 Q2 | 1.58 Billion INR | -7.53% |
2023 Q2 | 6.09 Billion INR | 15.54% |
2023 FY | 6.71 Billion INR | -34.14% |
2023 Q4 | 1.69 Billion INR | -75.55% |
2023 Q3 | 6.94 Billion INR | 14.08% |
2023 Q1 | 5.27 Billion INR | 112.62% |
2022 Q4 | 2.47 Billion INR | -4.37% |
2022 Q3 | 2.59 Billion INR | -2.08% |
2022 Q2 | 2.64 Billion INR | 6.83% |
2022 FY | 10.19 Billion INR | 16.61% |
2022 Q1 | 2.47 Billion INR | 10.96% |
2021 Q3 | 2.38 Billion INR | 15.95% |
2021 Q1 | 2.06 Billion INR | 34.09% |
2021 Q2 | 2.05 Billion INR | -0.21% |
2021 FY | 8.74 Billion INR | 20.12% |
2021 Q4 | 2.23 Billion INR | -6.48% |
2020 Q1 | 1.75 Billion INR | 74.42% |
2020 Q4 | 1.53 Billion INR | -27.83% |
2020 Q3 | 2.13 Billion INR | 15.31% |
2020 Q2 | 1.84 Billion INR | 5.17% |
2020 FY | 7.28 Billion INR | 19.89% |
2019 Q3 | 1.8 Billion INR | 0.0% |
2019 Q4 | 1 Billion INR | -44.28% |
2019 Q1 | 1.47 Billion INR | 0.0% |
2019 FY | 6.07 Billion INR | 16.27% |
2018 FY | 5.22 Billion INR | 13.26% |
2017 FY | 4.61 Billion INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Abbott India Limited | 5.98 Billion INR | 35.491% |
Cipla Limited | 59.21 Billion INR | 93.479% |
GlaxoSmithKline Pharmaceuticals Limited | 4.35 Billion INR | 11.377% |
Kopran Limited | 859.54 Million INR | -349.26% |
Marksans Pharma Limited | 3.28 Billion INR | -17.394% |
NGL Fine-Chem Limited | 816.16 Million INR | -373.141% |
Pfizer Limited | 4.33 Billion INR | 10.965% |
Sanofi India Limited | 3.69 Billion INR | -4.566% |
SMS Pharmaceuticals Limited | 370.89 Million INR | -941.166% |